Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of erlotinib in treating patients who have
metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies
such as erlotinib may interfere with the growth of tumor cells and slow the growth of the
tumor